Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
SELLAS Life Sciences Group, Inc. SLS
$1.53
-$0.16 (-10.53%)
На 18:01, 12 мая 2023
+357.52%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
48333170.00000000
-
week52high
5.58
-
week52low
1.17
-
Revenue
1000000
-
P/E TTM
-1
-
Beta
2.25328700
-
EPS
-2.16000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | Overweight | 28 июн 2022 г. |
| Cantor Fitzgerald | Overweight | 21 июл 2021 г. | |
| Oppenheimer | Outperform | 18 ноя 2019 г. | |
| Maxim Group | Buy | Hold | 18 ноя 2019 г. |
| Alliance Global Partners | Buy | 18 ноя 2019 г. | |
| Alliance Global Partners | Buy | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Burns John Thomas | A | 75000 | 75000 | 02 февр 2023 г. |
| Burns John Thomas | A | 49347 | 20000 | 02 февр 2023 г. |
| WOOD BARBARA A | A | 80000 | 80000 | 02 февр 2023 г. |
| WOOD BARBARA A | A | 76344 | 20000 | 02 февр 2023 г. |
| Stergiou Angelos M. | A | 217500 | 217500 | 02 февр 2023 г. |
| Stergiou Angelos M. | A | 219689 | 58000 | 02 февр 2023 г. |
| Varian John | A | 9500 | 9500 | 02 февр 2023 г. |
| Varian John | A | 4400 | 2500 | 02 февр 2023 г. |
| Francomano Robert | A | 45000 | 45000 | 02 февр 2023 г. |
| Francomano Robert | A | 12000 | 12000 | 02 февр 2023 г. |
Новостная лента
Sellas Life Sciences raises $20 million from public offering of stock, warrants
Market Watch
24 февр 2023 г. в 08:42
Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which is focused on cancer treatments, plummeted 43.1% in premarket trading, after the offering was initially announced without terms late Thursday.
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
InvestorPlace
24 февр 2023 г. в 08:29
SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public offering. According to a press release, SELLAS Life Sciences intends to offer up shares of SLS stock, as well as warrants to purchase shares of the stock.
SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire
03 ноя 2022 г. в 09:36
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology (ASH) Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana. The meeting will also take place virtually.
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
GlobeNewsWire
02 ноя 2022 г. в 08:30
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.
SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
Benzinga
08 июн 2022 г. в 12:11
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE: BMY) nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM). The trial included patients.